OR WAIT null SECS
After a six-month effort to validate both technological elements and international regulatory capabilities, ACM was able to confirm that Cryoport’s dry-vapor technology is in compliance with the stringent global regulatory standards and stable temperature profiles to ensure specimen viability. As part of ACM’s comprehensive validation effort, the company assessed the movement and temperature profile of almost 600 unique specimens over a multitude of shipping lanes, including international clinical trial hubs in India, China, Southeast Asia, and Europe. ACM is now offering this cold chain shipping solution at significant cost savings compared to dry ice shipping methods to its global customers.
The reusable CryoPort Express LN2 Dry Vapor Shipper is designed to meet the needs of clinical labs, diagnostic companies, research organizations, and the biotech and pharmaceutical industries by allowing tissue samples, blood, and other biological material to remain frozen at or below -150ºC for 10+ days, in contrast to the current industry practice of dry-ice packaging, which often requires re-icing during transit.
“ACM is proud to move this technology into production mode. With international courier costs consuming a significant portion of all global protocol budgets, we believe this new service offering from Cryoport can be an attractive alternative. Not only is the actual shipment more cost effective, the increased cost of adding more dry ice during transit to protect specimen integrity is eliminated,” said Tracy Hendershott, ACM Global’s vice president of clinical trials. “Cryoport has been extremely collaborative in complying with ACM’s stringent validation efforts, and now we look forward to sharing that benefit with our global clients.”